Experiences with
Ibrutinib2,003 public posts
iwCLL 2019 | Five-year follow up of the UK CLL Forum ibrutinib data
Dr Toby Eyre, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the UK chronic lymphocytic leukemia (CLL) forum study led by George Follows, Cambridge University Hospitals, Cambridge, UK, and the 5-year follow up data for ibrutinib in R/R CLL.
Want to take advantage of all our features? Just log in!
or
Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Intensification of Therapy in CLL
Following induction therapy, those patients with a complete response (CR) and bone marrow MRD status of less than .01% were treated with 6 months of ibrutinib; whereas those achieving a partial response (PR), or a CR and bone marrow MRD greater than or equal to .01%, received 6 months of ibrutinib plus
Ibrutinib‐associated Pneumocystis jirovecii pneumonia - do we need prophylaxis?
Dr Guilherme Perini's study of PJP and fungal prophylaxis deduced that it is probably not needed in ibrutinib treated patients.
Prevalence was 3.4% in patients not receiving prophylaxis and 0% in those that were.
Ibrutinib Shown to Cross the Blood-Brain Barrier in CNS Lymphoma
More information here: https://www.cancertherapyadvisor.com/home/cancer-topics/lymphoma/cns-lymphoma-ibrutinib-shown-to-cross-blood-brain-barrier/?
Novel Combos Are Shaking Up the CLL Landscape but FCR still has its place
Patients received 3 cycles of iFCG followed by ibrutinib for 9 cycles and obinutuzumab for either 3 or 9 cycles, depending upon response and MRD levels. After 12 cycles, ibrutinib therapy stopped for those with undetectable bone marrow and continued for those with detectable MRD.
ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
This time at ASH 2018, we also discussed his innovative research using claims data from 2014- 2017 on the total cost of care for CLL patients who took ibrutinib versus chemotherapy or chemo-immunotherapy (CT/CIT).
Guess what- The total cost is cheaper with ibrutinib.